Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)

This study excluded an increased risk of the primary endpoint of more than two events per 1000 patient-years associated with switching to prescribed celecoxib.Clinical Trial Registrationhttps://clinicaltrials.gov/show/NCT00447759; Unique identifier: NCT00447759.
Source: European Heart Journal - Category: Cardiology Source Type: research